Fostamatinib Phase 3 Study in ITP Results (Replay)
August 30, 2016 at 8:00 a.m. ET
Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.
Recent NewsMore »
|08/30/16||Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP|
|Conference call and webcast today at 8:00 AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical program for the treatment of adult chronic/persistent immune thrombocytopenia (ITP). The study (n=76) showed that 18% of patients receiving fostamatinib achi... |
|08/29/16||Rigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016|
|SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) on Tuesday, August 30, 2016. The company will also host a conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 study results.
Participants can access the... |
|08/02/16||Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update|
|Conference Call and Webcast Today at 5:00 PM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2016.
"We look forward to announcing the topline results for the first of two Phase 3 studies of fostamatinib in patients with ITP by the end of this August, followed by the second study's results a few months later," said Raul Rodriguez, president... |
Upcoming EventsMore »
There are currently no events scheduled.
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|